Venture financing ticks up for biopharma
But, with an ever-growing proportion of the cash going to a select few, the gulf between the haves and the have-nots is widening.
Medtech dealmaking grinds almost to a halt
M&A moves are down, venture rounds few and IPOs nonexistent.
Orbital shows 2023’s venture funding scene is far from stratospheric
The group’s $270m series A, big for 2023, is not that impressive compared with other years.
Sofinnova goes digital
The promise of fast timelines and early revenues lure a new investor into digital medicine.
A lean first quarter for venture-backed developers
While venture investors keep the purse strings tight, they themselves continue to enjoy fundraising success.
Biopharma’s venture year ends with another dip
Last year saw plenty of cash deployed, but with sums shrinking each quarter the stage is set for further retrenchment.